| Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial N Tessitore, V Bedogna, A Poli, G Lipari, P Pertile, E Baggio, A Contro, ... Nephrology Dialysis Transplantation 29 (1), 179-187, 2014 | 53 | 2014 |
| A Bayesian decision theoretic model of sequential experimentation with delayed response S Chick, M Forster, P Pertile Journal of the Royal Statistical Society Series B: Statistical Methodology …, 2017 | 46 | 2017 |
| Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies P Pertile, M Forster, DL Torre Journal of the Royal Statistical Society Series A: Statistics in Society 177 …, 2014 | 42 | 2014 |
| The impact of managed entry agreements on pharmaceutical prices S Gamba, P Pertile, S Vogler Health economics 29, 47-62, 2020 | 32 | 2020 |
| Static and dynamic efficiency of irreversible health care investments under alternative payment rules R Levaggi, M Moretto, P Pertile Journal of Health Economics 31 (1), 169-179, 2012 | 25 | 2012 |
| Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective M Forster, P Pertile Health Economics 22 (12), 1507-1514, 2013 | 24 | 2013 |
| An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography P Pertile International journal of health care finance and economics 9, 317-332, 2009 | 21 | 2009 |
| Late-stage pharmaceutical R&D and pricing policies under two-stage regulation S Jobjörnsson, M Forster, P Pertile, CF Burman Journal of health economics 50, 298-311, 2016 | 20 | 2016 |
| A large scale OLG model for the analysis of the redistributive effects of policy reforms A Bucciol, L Cavalli, I Fedotenkov, P Pertile, V Polin, N Sartor, ... European Journal of Political Economy 48, 104-127, 2017 | 19 | 2017 |
| The dynamics of pharmaceutical regulation and R&D investments R Levaggi, M Moretto, P Pertile Journal of Public Economic Theory 19 (1), 121-141, 2017 | 19 | 2017 |
| Value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition R Levaggi, P Pertile Applied Health Economics and Health Policy 18 (3), 357-362, 2020 | 17 | 2020 |
| Investment in health technologies in a competitive model with real options P Pertile Journal of Public Economic Theory 10 (5), 923-952, 2008 | 17 | 2008 |
| Two-part payments for the reimbursement of investments in health technologies R Levaggi, M Moretto, P Pertile Health Policy 115 (2-3), 230-236, 2014 | 16 | 2014 |
| Which valued‐based price when patients are heterogeneous? R Levaggi, P Pertile Health economics 29 (8), 923-935, 2020 | 14 | 2020 |
| The timing of adoption of positron emission tomography: a real options approach P Pertile, E Torri, L Flor, S Tardivo Health care management science 12, 217-227, 2009 | 13 | 2009 |
| Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy P Pertile, A Poli, L Dominioni, N Rotolo, E Nardecchia, M Castiglioni, ... Cost Effectiveness and Resource Allocation 13, 1-12, 2015 | 12 | 2015 |
| R&D and market size: Who benefits from orphan drug legislation? S Gamba, L Magazzini, P Pertile Journal of Health Economics 80, 102522, 2021 | 10 | 2021 |
| Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial M Forster, S Brealey, S Chick, A Keding, B Corbacho, A Alban, P Pertile, ... Clinical trials 18 (6), 647-656, 2021 | 9 | 2021 |
| Redistribution at the local level: the case of public childcare in Italy A Bucciol, L Cavalli, P Pertile, V Polin, A Sommacal International Review of Economics 63, 359-378, 2016 | 9 | 2016 |
| L’ISEE in Italia: Una nota metodologica partendo dai dati IT-SILC A Bucciol, L Cavalli, E Dalla Chiara, M Menon, P Pertile, V Polin, ... University of Verona, Department of Economics Working Papers, 2014 | 7 | 2014 |
